A promising new non-surgical treatment for nonmelanoma skin cancer, known as Image-Guided Superficial Radiation Therapy (IGSRT), has become available to patients, showcasing an impressive 99.3% cure rate for early-stage nonmelanoma. This cutting-edge procedure uses ultrasound imaging to direct low-level x-rays at specific areas, eliminating cancer cells without the complications of bleeding, pain, or surgical scarring. Furthermore, it negates the need for any subsequent reconstructive surgery.
The GentleCure treatment, heralded as an equally effective alternative to conventional surgical treatments, comes as a significant advancement in the field of dermatology. Historically, nonmelanoma skin cancer treatments often involved patients undergoing Mohs surgery. Yet, the advent of IGSRT presents a less invasive solution, avoiding residual scars and reducing pain.
Dr. Denise T. Dickinson, a board-certified dermatologist based in Louisville, Kentucky, is pioneering this treatment in the state. Her practice holds the distinction of being Kentucky’s inaugural office to provide the IGSRT treatment. Commenting on this revolutionary approach, Dr. Dickinson stressed the continued importance of traditional Mohs surgery for certain non-melanoma skin cancers, emphasizing the need to ensure patients are aware of both surgical and non-surgical options.
Kerwin Brandt, the CEO of SkinCure Oncology, shared the company’s commitment to expanding patient knowledge about Image-Guided Superficial Radiation Therapy. Their surveys demonstrate a 99.8% satisfaction rate amongst patients treated with Image-Guided SRT. Over the past six years, SkinCure Oncology, the global leader in delivering Image-Guided SRT, has partnered with around 500 physicians across the nation, providing this treatment to more than 60,000 patients.
Abstract of original research
The Treatment of Non-Melanoma Skin Cancer with Image-Guided Superficial Radiation Therapy: An Analysis of 2917 Invasive and In Situ Keratinocytic Carcinoma Lesions
Abstract – Introduction: An image-guided form of superficial ionizing radiation therapy (IGSRT) is becoming a commonly used alternative to surgery for non-melanoma skin cancer (NMSC). However, there is little literature evidence evaluating the efficacy and safety of this approach. This study evaluates the efficacy and safety of IGSRT in treating a large number of patients with NMSC.
Methods: The medical records of 1632 stage 0–II patients with 2917 invasive and in situ NMSC lesions treated from years 2017 to 2020 were reviewed. No patients had clinical evidence of regional lymph node or distant disease at presentation.
Results: Treatment, guided by pre-treatment ultrasound imaging to adjust radiation energy and dose, combined with a fractionation treatment schedule of 20 or more treatment fractions, was safe and well tolerated. Of 2917 NMSC lesions treated, local tumor control was achieved in 2897 lesions, representing a 99.3% rate of control.
Conclusion: IGSRT should be considered as a first-line option for treating NMSC tumors in suitable early stage patients. Cure rates observed in this initial period of follow-up are similar, and potentially superior with further follow-up, to traditional superficial radiation therapy (SRT) and surgical options. For full text of article click this link:>>>